

Effectiveness of the BNT162b2 vaccine in preventing COVID-19 in the working age population – first results from a cohort study in Southern Sweden

Jonas Björk^{1,2}, Malin Inghammar³, Mahnaz Moghaddassi⁴, Magnus Rasmussen³, Ulf Malmqvist², Fredrik Kahn³

¹Division of Occupational and Environmental Medicine, Lund University, Lund, Sweden

²Clinical Studies Sweden, Forum South, Skåne University Hospital, Lund, Sweden

³Department of Clinical Sciences Lund, Section for Infection Medicine, Skåne University Hospital, Lund University, Lund, Sweden

⁴Social Medicine and Global Health, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden

Supporting information

Table S1. Effectiveness of the BNT16b2 mRNA (Pfizer-BioNTech) vaccine in preventing SARS-CoV-2 infection during period 1-3 (27 December 2020 – 14 February 2021).

Table S2. Effectiveness of the BNT16b2 mRNA (Pfizer-BioNTech) vaccine in preventing SARS-CoV-2 infection during period 4 (15 – 28 February 2021) and stratified by sex.

Table S3. Effectiveness of the BNT16b2 mRNA (Pfizer-BioNTech) vaccine on COVID-19 mortality during follow up 27 December 2020 – 28 February 2021.

Table S1. Effectiveness of the BNT16b2 mRNA (Pfizer-BioNTech) vaccine in preventing SARS-CoV-2 infection during period 1-3 (27 December 2020 – 14 February 2021).

	27 Dec 2020 – 17 Jan 2021			18 – 31 Jan 2021			1 – 14 Feb 2021			
	Cases, n	Person-time, weeks	Incidence (95% CI) ^a	Cases, n	Person-time, weeks	Incidence (95% CI) ^a	Cases, n	Person-time, weeks	Incidence (95% CI) ^a	Effectiveness, % (95% CI)
<u>No prior positive test</u>										
Unvaccinated or before 1 st dose	20 215	2 257 089	896 (883 – 908)	6 885	1 451 061	474 (463 – 486)	4 787	1 426 823	336 (326 – 345)	Ref.
1 st dose, day 0-13	51	7 088	720 (522 – 917)	176	21 884	804 (685 – 923)	46	10 795	426 (303 – 549)	-
1 st dose, day 14-	3	488	615 (127 – 1 797)	22	7 711	285 (166 – 405)	55	21 952	251 (184 – 317)	25 (2.6 – 44)

2 nd dose, day 0-6	-	-	-	-	-	-	3	5 397	56 (11 – 162)	83 (52 – 97)
2 nd dose, day 7-	-	-	-	-	-	-	1	4 078	25 (0.6 – 137)	93 (59 – 100)
<u>Prior positive test</u> ^b										
Unvaccinated or before 1 st dose	NR	NR	NR	21	77 288	28 (16 – 39)	15	75 767	19 (9 – 29)	94 (90 – 97)

^aCases per 100 000 persons and week (95% confidence interval). Results from statistical analysis were weighted with respect to sex and age distribution of the vaccinated cohort.

^bThe number of vaccinated with prior positive test was too few to permit evaluation of vaccine effectiveness

Table S2. Effectiveness of the BNT16b2 mRNA (Pfizer-BioNTech) vaccine in preventing SARS-CoV-2 infection during period 4 (15 – 28 February 2021) and stratified by sex.

	Females				Males			
	Cases, n	Person-time, weeks	Incidence (95% CI) ^a	Effectiveness, % (95 CI)	Cases, n	Person-time, weeks	Incidence (95% CI) ^a	Effectiveness, % (95 CI)
<u>No prior positive test</u>								
Unvaccinated or before 1 st dose	3 313	1 129 981	293 (283 – 303)	Ref.	842	285 208	295 (275 – 315)	Ref.
1 st dose, day 0-13	8	15 914	503 (154 – 851)	-	1	669	149 (3.8 – 833)	-
1 st dose, day 14-	22	11 738	187 (109 – 266)	36 (3.0 – 60)	3	2 952	102 (21 – 297)	66 (0.0 – 93)

2 nd dose, day 0-6	9	7 016	128 (44 – 212)	56 (17 – 80)	1	1 521	66 (17 – 366)	78 (0.0 – 99)
2 nd dose, day 7-	6	15 397	39 (8 – 70)	87 (71 – 95)	2	3 690	54 (6.6 – 196)	82 (33 – 98)
<u>Prior positive test</u> ^b								
Unvaccinated or before 1 st dose	20	62 265	31 (18 – 45)	89 (83 – 93)	1	13 134	7.6 (0.2 – 42)	97 (86 – 100)

^aCases per 100 000 persons and week (95% confidence interval). Results from statistical analysis were weighted with respect to sex and age distribution of the vaccinated cohort.

^bThe number of vaccinated with prior positive test was too few to permit evaluation of vaccine effectiveness

Table S3. Effectiveness of the BNT16b2 mRNA (Pfizer-BioNTech) vaccine on COVID-19 mortality during follow up 27 December 2020 – 28 February 2021.

	Deaths	Person-time, weeks	Mortality rate (95% CI) ^a
Unvaccinated or before 1 st dose	36	7 102 506	0.5 (0.3 – 0.7)
1 st dose, day 0-13	0	48 257	0.0 (0.0 – 7.6)
1 st dose, day 14-	0	52 102	0.0 (0.0 – 7.1)
2 nd dose, day 0-6	0	16 544	0.0 (0.0 – 22.0)
2 nd dose, day 7-	0	26 725	0.0 (0.0 – 13.8)

^aDeaths per 100 000 persons and week (95% confidence interval). Results from statistical analysis were weighted with respect to sex and age distribution of the vaccinated cohort.